Welcome to our dedicated page for Biocryst Pharmaceuticals SEC filings (Ticker: BCRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) files a range of documents with the U.S. Securities and Exchange Commission that shed light on its operations as a biotechnology company focused on hereditary angioedema (HAE) and other rare diseases. On this page, you can review BioCryst’s SEC filings alongside AI-generated summaries that help explain complex disclosures in clear language.
Current Reports on Form 8-K are especially important for tracking material events at BioCryst. Recent 8-K filings describe key regulatory milestones, such as U.S. Food and Drug Administration approval of the New Drug Application for an oral pellet formulation of once-daily ORLADEYO® (berotralstat) for prophylactic therapy in pediatric HAE patients aged 2 to <12 years. Other 8-Ks cover quarterly financial results, preliminary revenue updates, and guidance for ORLADEYO net revenue, total revenue including RAPIVAB® (peramivir injection), and non-GAAP operating expenses.
Filings also document strategic transactions that shape BioCryst’s business model. One set of 8-Ks details the Stock Purchase Agreement and subsequent closing of the sale of BioCryst Ireland Limited, which held certain assets and rights related to the European ORLADEYO business, along with associated IP license, supply, brand support, transition services, and trademark license agreements. Another 8-K outlines the Agreement and Plan of Merger under which a BioCryst subsidiary will merge with Astria Therapeutics, Inc., including the cash-and-stock merger consideration, closing conditions, and potential delisting of Astria’s stock.
Governance and compensation developments also appear in BioCryst’s filings. Recent 8-Ks describe the planned retirement of the company’s President and Chief Executive Officer, the appointment of a new President and future CEO, the hiring of a new Chief Financial Officer, and related employment and separation agreements. Additional filings report inducement equity grants to new employees in accordance with Nasdaq Listing Rule 5635(c)(4).
Alongside these 8-Ks, investors can use this page to access BioCryst’s periodic reports on Forms 10-K and 10-Q (when available), which provide detailed discussions of risk factors, business strategy, and financial statements. Stock Titan’s AI tools highlight key sections of lengthy documents such as annual reports (10-K), quarterly reports (10-Q), and insider transaction filings (Form 4), helping you quickly understand revenue drivers, major agreements, executive changes, and other disclosures that may affect BCRX.
BioCryst Pharmaceuticals furnished a press release announcing recent corporate developments and financial results for the third quarter ended September 30, 2025. The company also referenced a conference call and webcast to discuss these updates.
The press release is attached as Exhibit 99.1. The information was furnished, not filed, which means it is not subject to Section 18 liability and is not incorporated into other filings unless specifically referenced.
BioCryst Pharmaceuticals (BCRX) agreed to acquire Astria Therapeutics via a cash-and-stock merger. Each Astria share will be exchanged for $8.55 in cash plus 0.59 of a BioCryst common share, with a cap that limits total new BioCryst shares to 19.9% of pre-close shares; if that cap is reached, the share portion decreases and the cash portion increases by the same value.
Closing is subject to Astria stockholder approval, HSR clearance, SEC effectiveness of a Form S-4 registering the BioCryst shares, Nasdaq listing approval for the new shares, and other customary conditions. The companies anticipate closing in the first quarter of 2026. Under specified circumstances, Astria would owe BioCryst a $32,250,000 termination fee.
BioCryst obtained a $550,000,000 senior secured debt commitment from Blackstone, including a $350,000,000 initial term loan and a $50,000,000 committed delayed draw, to help fund the consideration and related fees at closing. BioCryst also fully repaid and terminated its prior BioPharma Credit loan. Subject to the merger’s effective time, Astria CEO Jill C. Milne, Ph.D. is expected to join the BioCryst board, with an initial equity grant valued at $500,000.
BioCryst Pharmaceuticals, Inc. filed a Form 8-K reporting the consummation of a Transaction and furnishing a set of related agreements dated October 1, 2025. The filing lists six exhibits between the company and BioCryst Ireland: an Amended and Restated IP Licence Agreement, a Supply Agreement, a Global Brand and Support Agreement, a Transition Services Agreement, a Trademark License Agreement, and a Press Release regarding the Transaction. The filing states that schedules and exhibits to those agreements were omitted from the public filing under Item 601(a)(5) of Regulation S-K and are available to the SEC on request.
Deerfield-affiliated entities and individual James E. Flynn report a 5.80% beneficial ownership stake in BioCryst Pharmaceuticals common stock, representing 12,169,000 shares. The filing states that all reporting persons have no sole voting or dispositive power and instead hold shared voting and dispositive power over 12,169,000 shares. The reporting group consists of Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P. and James E. Flynn, organized in Delaware (entities) and the United States (Flynn). The filing includes a joint filing agreement, an Item 8 statement and a previously filed power of attorney exhibit. Signatures are dated 09/19/2025.
Amy E. McKee, a director of BioCryst Pharmaceuticals, acquired 676 shares of the company's common stock on 08/29/2025 at a price of $8.31 per share. The shares were issued in lieu of 50% of her quarterly cash board retainer of $11,250. After the transaction, Ms. McKee beneficially owns 41,007 shares, held directly. The Form 4 was signed by Alane P. Barnes by power of attorney on 09/03/2025. This filing reports a routine director compensation conversion into equity and does not disclose other changes to ownership or derivative positions.
Frank Steven, a director of BioCryst Pharmaceuticals, acquired 1,353 shares of the company's common stock on 08/29/2025 at a price of $8.31 per share, bringing his total beneficial ownership to 16,052 shares. The shares were issued in lieu of a quarterly cash board retainer equal to $11,250, representing an election to receive equity rather than cash compensation.
This disclosure is a routine Section 16 filing reporting a director compensation-related share issuance; it reflects non-derivative, direct ownership and does not indicate any sale or derivative transactions.
BioCryst Pharmaceuticals director Vincent Milano reported an equity-based compensation transaction: on 08/29/2025 he was issued 676 shares of Common Stock at an effective price of $8.31 per share, increasing his direct beneficial ownership to 90,436 shares. The filing explains the shares were issued in lieu of 50% of the quarterly cash board retainer of $11,250, indicating part of the director's compensation was taken in stock rather than cash. The Form 4 was signed by power of attorney on 09/03/2025.
Insider trades by director Theresa Heggie at BioCryst Pharmaceuticals (BCRX): the filing shows automatic option grants and a sale on 08/13/2025. She received two automatic option grants totaling 70,000 options (30,000 at $2.91; 40,000 at $5.41) exercisable in 2020 and 2021 with 2029 and 2030 expirations. On the same date she sold 70,000 common shares at a weighted average price of $8.5124, leaving her with 65,352 shares beneficially owned.
BioCryst Pharmaceuticals (BCRX) Form 144 notifies a proposed sale of 70,000 common shares through Fidelity Brokerage Services with an aggregate market value of $595,870.74. The shares are scheduled for sale on 08/13/2025 on NASDAQ and come from a reported total outstanding share count of 209,920,430.
The filing shows the shares derive from stock options: 30,000 from an option granted 05/29/2019 and 40,000 from an option granted 05/12/2020, with the consideration listed as cash. The filer reports Nothing to Report for sales in the past three months and includes the standard representation that no undisclosed material adverse information is known to the seller.
BioCryst Pharmaceuticals, Inc. has registered 11,000,000 shares of common stock for issuance under its Stock Incentive Plan, which was amended and restated on April 21, 2025 and approved by stockholders on June 12, 2025. The Registration Statement incorporates by reference the companys Annual Report for the year ended December 31, 2024 and Quarterly Reports filed for the quarters ended March 31, 2025 and June 30, 2025, as well as a series of Current Reports filed between February and August 2025.
The filing describes the companys indemnification framework under Delaware law, noting statutory protections under Section 145 and Section 102(b)(7), the Certificate of Incorporation and Bylaws indemnification provisions, and existing directors and officers liability insurance. The filing also states that indemnification for Securities Act liabilities may be deemed unenforceable under SEC precedent. Exhibits include counsels opinion, auditor consent, the amended Stock Incentive Plan (incorporated by reference), a power of attorney, and the fee table.
FAQ
What is the current stock price of Biocryst Pharmaceuticals (BCRX)?
What is the market cap of Biocryst Pharmaceuticals (BCRX)?
